. Author manuscript; available in PMC: 2017 Jul 12.

Published in final edited form as: HIV Med. 2016 Apr 28;18(1):13–20. doi: 10.1111/hiv.12387

Table 2.

Short-term Mortality Risk by Hemoglobin Status.

		Grade 2-4 Baseline Hemoglobin, <8.5g/dL				Grade 3-4 Baseline Hemoglobin, <7.5g/dL
		Unadjusted		Adjusted^‡		Unadjusted		Adjusted^‡
	N	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value
2-week mortality	311	1.97 (1.12, 3.45)	0.02	2.69 (1.46, 4.93)	<0.01	1.23 (0.52, 2.91)	0.64	1.41 (0.57, 3.45)	0.46

10-week mortality	311	1.55 (0.95, 2.52)	0.08	1.82 (1.05, 3.15)	0.03	1.24 (0.62, 2.45)	0.54	1.18 (0.53, 2.62)	0.69

		Grade 2-4 Nadir Hemoglobin, <8.5g/dL				Grade 3-4 Nadir Hemoglobin, <7.5g/dL
		Unadjusted		Adjusted^‡		Unadjusted		Adjusted^‡
	N	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value

10-week mortality^*	98	2.80 (0.82, 9.50)	0.10	2.03 (0.45, 9.12)	0.35	1.10 (0.44, 2.78)	0.83	0.70 (0.25, 1.92)	0.49

^‡

Comparison of patients with hemoglobin <8.5g/dL to those with hemoglobin ≥8.5g/dL, adjusted for patient sex, age (>50 years or ≤50 years), ART status at enrollment, prior history of cryptococcal meningitis, log₁₀ quantitative CSF cultures/mL, and Glasgow Coma Scale score <15 at baseline.

Among COAT participants who survived for two weeks only, which had systematic follow up hemoglobin measurements during the first two weeks.